Allergan reports continued strong growth in second quarter of 2016

Allergan has announced its financial results for the second quarter of 2016, during which it delivered a net revenue total of $3.7 billion (2.85 billion pounds).

This represents a year-on-year increase of two percent, with a strong performance by key brands and the success of recent product launches helping to offset the impact of Namenda IR's loss of market exclusivity.

Products such as Botox, Restasis, Linzess, Juvederm and Lo Loestrin all helped to drive this momentum, with 13 major US and international approvals secured and nine major regulatory submissions made during the quarter.

Other key milestones include the sale of the company's global generics business to Teva, a move that marks Allergan's transition to becoming a purely branded medicines-focused organisation.

Brent Saunders, chief executive officer and president of Allergan, said: "Allergan delivered another quarter of strong operating performance, while taking important steps to advance our evolution as a focused growth pharma leader."

The company also announced in the last week that it has signed a deal to acquire ForSight VISION5, the developer of new technology for the treatment of glaucoma.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.